



## Press Release

Bangalore, November 25, 2010

Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

BSE: 532531  
NSE: STAR

---

## STRIDES SPECIALTIES REBRANDED AS AGILA SPECIALTIES


- *New name reflective of Strides' focus on specialties*
  - *Venkat Iyer appointed as Chief Executive Officer*
- 

Strides Arcolab Limited (Strides) today announced that its Specialties division, Strides Specialties Private Limited which was spun off as a separate division post the restructuring announced in 2009, will now be known as Agila Specialties Private Limited. It will continue to function as a wholly owned subsidiary of Strides Arcolab Limited (BSE: 532531, NSE: STAR). The name Agila reflects the brand ethos of Strides' specialised product offering which is smart, agile, determined and pragmatic.

Concurrent with this announcement, Strides also announced the appointment of Venkat Iyer as Chief Executive Officer of Agila Specialties. Venkat has been with Strides for 11 years and in the healthcare industry for 28 years. Earlier this year he was inducted onto the Board of Strides Arcolab Limited as an Executive Director

“Against the rapid growth of our Specialties division and the increasing role it is playing in our Company's growth, we felt the need for a new identity that will reflect our position in this dynamic and challenging segment of the healthcare industry,” said Arun Kumar, Vice Chairman and Group CEO, Strides Arcolab Limited. “The new identity also communicates our seriousness and intent to be a steriles powerhouse. I have no doubt that under Venkat's leadership, Agila will only grow in stature and reputation.”

With a world class sterile injectables platform, robust product pipeline and record regulatory filings, hi-tech manufacturing capacities across countries, an impeccable record of quality and marquee customers and partners across the healthcare industry, Agila Specialties is well positioned to build a distinct identity for itself in the industry. Strategic partnerships with the big pharma, continuing licensing income and new product launches in regulated markets have been key growth drivers for the Company.



“I am delighted to assume leadership of Agila Specialties at a very exciting stage in our growth,” said Venkat Iyer. “Our focus on key domains has given us a competitive advantage in the industry, validated by the recent partnerships we have entered into with GSK and Pfizer. We will consolidate and build on our domain portfolio while exploring opportunities for more partnerships against the background of growing convergence in the industry.”

Agila Specialties will operate from 7 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. The Company is focused on key therapeutic areas like anti-infectives, oncology, CNS, GI, ophthalmics and peptides.

Agila Specialties is in the process of rolling out its new brand identity across the globe. While the Company will share some common administrative resources with the Strides Group, all employees of the erstwhile Strides Specialties division will now be employees of Agila Specialties.

**About Strides Arcolab Limited:**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company’s website at [www.stridesarco.com](http://www.stridesarco.com).

For further information, please contact:

Mr. Arun Kumar (Vice Chairman & Group CEO) Ph: +91 80 6658 0118	Mr. Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: <a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a>
Mr. N Kannan (Investor Relations) Tel : +91 98450 54745	Ms. Kasturi Wasmatkar, Corporate Voice/ Weber Shandwick Mobile: 99167 28393 Email: <a href="mailto:kasturi@corvoshandwick.co.in">kasturi@corvoshandwick.co.in</a>
Ms. Melissa Arulappan (Media) Tel: +91 98450 22389	

